Tamoxifen-resistant breast cancer cells are resistant to DNA-damaging chemotherapy because of upregulated BARD1 and BRCA1

Tamoxifen resistance is accountable for relapse in many ER-positive breast cancer patients. Most of these recurrent patients receive chemotherapy, but their chemosensitivity is unknown. Here, we report that tamoxifen-resistant breast cancer cells express significantly more BARD1 and BRCA1, leading to resistance to DNA-damaging chemotherapy including cisplatin and adriamycin, but not to paclitaxel. Silencing BARD1 or BRCA1 expression or inhibition of BRCA1 phosphorylation by Dinaciclib restores the sensitivity to cisplatin in tamoxifen-resistant cells. Furthermore, we show that activated PI3K/AKT pathway is responsible for the upregulation of BARD1 and BRCA1. PI3K inhibitors decrease the expression of BARD1 and BRCA1 in tamoxifen-resistant cells and re-sensitize them to cisplatin both in vitro and in vivo. Higher BARD1 and BRCA1 expression is associated with worse prognosis of early breast cancer patients, especially the ones that received radiotherapy, indicating the potential use of PI3K inhibitors to reverse chemoresistance and radioresistance in ER-positive breast cancer patients. Most breast cancer patients are estrogen receptor positive and thus benefit from treatments that inhibit estrogen production; however, one third of tamoxifen-treated patients develops resistance and relapse. Here the authors show that tamoxifen resistant cells are resistant to chemotherapy because of BARD1 and BRCA1 upregulation.

• Publication year

  2018

• Venue

  Nature Communications

• Publication date

  2018-04-23

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/s41467-018-03951-0PMID 29686231PMCID 5913295
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Essential role of Notch4/STAT3 signaling in epithelial-mesenchymal transition of tamoxifen-resistant human breast cancer.

  2017cited by this paper
• 3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

  2017cited by this paper
• 3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3).

  2017cited by this paper
• miR-375 inhibits cancer stem cell phenotype and tamoxifen resistance by degrading HOXB3 in human ER-positive breast cancer.

  2017cited by this paper
• CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer.

  2016cited by this paper
• Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy–Resistant Breast Cancer

  2015cited by this paper
• E2F7 overexpression leads to tamoxifen resistance in breast cancer cells by competing with E2F1 at miR-15a/16 promoter

  2015cited by this paper
• The BRCA1/BARD1-interacting protein OLA1 functions in centrosome regulation.

  2014cited by this paper
• Sox2 promotes tamoxifen resistance in breast cancer cells

  2013cited by this paper
• The Wnt signalling pathway is upregulated in an in vitro model of acquired tamoxifen resistant breast cancer

  2013cited by this paper
• Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer

  2013cited by this paper
• Comprehensive molecular portraits of human breast tumours

  2013cited by this paper
• Function of BRCA1 in the DNA damage response is mediated by ADP-ribosylation.

  2013cited by this paper
• Hedgehog signaling is a novel therapeutic target in tamoxifen-resistant breast cancer aberrantly activated by PI3K/AKT pathway.

  2012cited by this paper
• Overexpression of CD44 accompanies acquired tamoxifen resistance in MCF7 cells and augments their sensitivity to the stromal factors, heregulin and hyaluronan

  2012cited by this paper
• Comprehensive molecular portraits of human breast tumors

  2012cited by this paper
• PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition.

  2012cited by this paper
• Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer.

  2011cited by this paper
• Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer.

  2011cited by this paper
• A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer.

  2011cited by this paper
• COMPROMISED CDK1 ACTIVITY SENSITIZES BRCA-PROFICIENT CANCERS TO PARP INHIBITION

  2011cited by this paper
• Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

  2011cited by this paper
• Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer

  2010cited by this paper
• Nuclear phosphoinositide 3-kinase β controls double-strand break DNA repair

  2010cited by this paper
• CDK inhibitors as potential breast cancer therapeutics: new evidence for enhanced efficacy in ER+ disease

  2009cited by this paper
• Biological determinants of endocrine resistance in breast cancer

  2009cited by this paper
• Cdk1 participates in BRCA1-dependent S phase checkpoint control in response to DNA damage.

  2009cited by this paper
• Fibroblast growth factor receptor 4 predicts failure on tamoxifen therapy in patients with recurrent breast cancer.

  2008cited by this paper
• Cyclin D1 Expression in Breast Cancer Patients Receiving Adjuvant Tamoxifen-Based Therapy

  2008cited by this paper
• Inhibition of Phosphatidylinositol-3-OH Kinase/Akt Signaling Impairs DNA Repair in Glioblastoma Cells following Ionizing Radiation*

  2007cited by this paper
• The BRCA1/BARD1 heterodimer modulates ran-dependent mitotic spindle assembly.

  2006cited by this paper
• Cyclin D1 is necessary for tamoxifen-induced cell cycle progression in human breast cancer cells.

  2006cited by this paper
• DNA damage-induced BARD1 phosphorylation is critical for the inhibition of messenger RNA processing by BRCA1/BARD1 complex.

  2006cited by this paper
• Is there more to BARD1 than BRCA1?

  2006cited by this paper
• Inhibition of mTOR Activity Restores Tamoxifen Response in Breast Cancer Cells with Aberrant Akt Activity

  2004cited by this paper
• Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells.

  2003cited by this paper
• Long-term hydroxytamoxifen treatment of an MCF-7-derived breast cancer cell line irreversibly inhibits the expression of estrogenic genes through chromatin remodeling.

  2000cited by this paper
• Both autocrine and paracrine effects of transfected acidic fibroblast growth factor are involved in the estrogen-independent and antiestrogen-resistant growth of MCF-7 breast cancer cells.

  1998cited by this paper
• BRCA1 is a cell cycle-regulated nuclear phosphoprotein.

  1997cited by this paper

• The hallmarks of oncogenic signaling: From pathways to resistance in cancer therapy.

  2026cites this paper
• SIRT7 Orchestrates Ligand‐Dependent ERα Signaling Rewiring to Drive Tamoxifen Resistance in ERα‐positive Breast Cancer

  2026cites this paper
• Pancreatic cancer organoids derived from EUS-guided fine needle aspiration specimens can be used to predict chemotherapy resistance

  2025cites this paper
• DNA repair and the contribution to chemotherapy resistance

  2025cites this paper
• Understanding drug resistance in breast cancer: Mechanisms and emerging therapeutic strategies

  2025cites this paper
• Facing the Challenge to Mimic Breast Cancer Heterogeneity: Established and Emerging Experimental Preclinical Models Integrated with Omics Technologies

  2025cites this paper
• Pilocytic astrocytoma with BARD1 mutation: oncogenic pathways via DNA damage repair mechanism and MAPK/BRAF.

  2025cites this paper
• Research Progress on PI3K/AKT/mTOR Signaling Pathway and Multidrug Resistance in Breast Cancer

  2025cites this paper
• ATE1 promotes breast cancer progression via arginylation-dependent regulation of MAPK-MYC signaling

  2025cites this paper
• Targeting BARD1 suppresses a Myc-dependent transcriptional program and tumor growth in pancreatic ductal adenocarcinoma

  2025cites this paper
• NUPR1 contributes to endocrine therapy resistance by modulating BIRC5 expression and inducing luminal B-ERBB2+ subtype-like characteristics in estrogen receptor-positive breast cancer cells

  2025cites this paper
• Lipoic acid-boronophenylalanine-derived multifunctional vesicles for cancer chemoradiotherapy

  2025cites this paper
• Soy Isoflavone Genistein Enhances Tamoxifen Sensitivity in Breast Cancer via microRNA and Glucose Metabolism Modulation

  2025cites this paper
• Molecular Insights on Signaling Cascades in Breast Cancer: A Comprehensive Review

  2025cites this paper
• BARD1: A Friend or Foe in Pancreatic Ductal Adenocarcinoma?

  2025cites this paper
• Contribution of BARD1 gene to male breast cancer- report of a family with different types of cancer.

  2025cites this paper
• Piwi-interacting RNA 775 (piR-775) predicts favorable prognosis and regulates cell cycle and DNA damage response pathways in breast cancer

  2025cites this paper
• CUEDC1 promotes glycolytic metabolism reprogramming through the CUEDC1/CACNG4/PI3K axis to promote ER-positive breast cancer growth

  2025cites this paper
• In Vitro Effects of Rumex confertus Extracts on Cell Viability and Molecular Pathways in MCF-7 Breast Cancer Cells

  2025influential citation
• hsa-mir-483-3p modulates delayed breast cancer recurrence

  2025cites this paper
• Fraxetin attenuates DNA damage and inflammation in cisplatin-induced nephrotoxicity via FoxO1 activation.

  2025cites this paper
• Knockdown of PVT1 inhibits cell proliferation in luminal and basal-like breast cancer subtypes by activating LATS2/Hippo signaling pathway

  2025cites this paper
• N6-methyladenosine-modified circPLPP4 sustains cisplatin resistance in ovarian cancer cells via PIK3R1 upregulation

  2024cites this paper
• Comprehensive review of drug resistance in mammalian cancer stem cells: implications for cancer therapy

  2024cites this paper
• The CDK12–BRCA1 signaling axis mediates dinaciclib‐associated radiosensitivity through p53‐mediated cellular senescence

  2024cites this paper
• HDAC-driven mechanisms in anticancer resistance: epigenetics and beyond

  2024cites this paper
• Advances in cancer diagnosis and therapy by alginate-based multifunctional hydrogels: A review.

  2024cites this paper
• Role of circRNAs in regulating cell death in cancer: a comprehensive review

  2024cites this paper
• Deubiquitinating enzyme USP28 inhibitor AZ1 alone and in combination with cisplatin for the treatment of non-small cell lung cancer

  2024cites this paper
• Impact of Molecular Profiling on Therapy Management in Breast Cancer

  2024cites this paper
• Molecular insights into epoxyazadiradione induced death in triple-negative breast cancer cells: A system biology approach.

  2024cites this paper
• Molecular Docking Study on Tamoxifen and Toremifene's Effects on the Breast Cancer Receptors

  2024cites this paper
• Current and emerging biomarkers in breast cancer: A review

  2024cites this paper
• The combination of temozolomide and perifosine synergistically inhibit glioblastoma by impeding DNA repair and inducing apoptosis

  2024cites this paper
• Modulation of homologous recombination gene activity in breast tumor cells in an in vitro model

  2024cites this paper
• Reversal of the tamoxifen‑resistant breast cancer malignant phenotype by proliferation inhibition with bromosulfonamidine amino‑podophyllotoxin

  2024cites this paper
• Dexamethasone–tamoxifen combination exerts synergistic therapeutic effects in tamoxifen-resistance breast cancer cells

  2024cites this paper
• A high-throughput approach to identify BRCA1-downregulating compounds to enhance PARP inhibitor sensitivity

  2024cites this paper
• DNA Damage Responses in Tumors Are Not Proliferative Stimuli, but Rather They Are DNA Repair Actions Requiring Supportive Medical Care

  2024cites this paper
• A novel bystander effect in tamoxifen treatment: PPIB derived from ER+ cells attenuates ER− cells via endoplasmic reticulum stress-induced apoptosis

  2024cites this paper
• The effect of human umbilical cord mesenchymal stem cells conditioned medium combined with tamoxifen drug on BRCA1 and BRCA2 expression in breast cancer mouse models

  2024cites this paper
• Recent advances in breast cancer cell line research

  2024cites this paper
• Establishing the role of BRCA1 in the diagnosis, prognosis and immune infiltrates of breast invasive cancer by bioinformatics analysis and experimental validation

  2024cites this paper
• Imperatorin-Loaded RH60/mPEG–PLLA Micelles for Reversing Tamoxifen Resistance in Breast Cancer

  2024cites this paper
• SERPINA3-ANKRD11-HDAC3 pathway induced aromatase inhibitor resistance in breast cancer can be reversed by HDAC3 inhibition

  2023cites this paper
• RelB-activated GPX4 inhibits ferroptosis and confers tamoxifen resistance in breast cancer

  2023cites this paper
• Small molecule inhibition of TFF3 overcomes tamoxifen resistance and enhances taxane efficacy in ER+ mammary carcinoma.

  2023cites this paper
• Crosstalk between endoplasmic reticulum stress and multidrug-resistant cancers: hope or frustration

  2023cites this paper
• Pan Cyclin-Dependent Kinase Inhibitors for the Treatment of Breast Cancer

  2023cites this paper
• E2F3 induces DNA damage repair, stem-like properties and therapy resistance in breast cancer.

  2023cites this paper
• Biomarkers in Breast Cancer: An Old Story with a New End

  2023cites this paper
• Targeting AKT Kinase in Hydroxytamoxifen-Resistant Breast Cancer Cells

  2023cites this paper
• SRSF5 Regulates the Expression of BQ323636.1 to Modulate Tamoxifen Resistance in ER-Positive Breast Cancer

  2023cites this paper
• A novel computational predictive biological approach distinguishes Integrin β1 as a salient biomarker for breast cancer chemoresistance.

  2023cites this paper
• Cluster of resistance-inducing genes in MCF-7 cells by estrogen, insulin, methotrexate and tamoxifen extracted via NMF.

  2023cites this paper
• Towards precision radiation oncology: endocrine therapy response as a biomarker for personalization of breast radiotherapy

  2023cites this paper
• Emerging role of GCN5 in human diseases and its therapeutic potential.

  2023cites this paper
• Tamoxifen resistance induction results in the upregulation of ABCG2 expression and mitoxantrone resistance in MCF-7 breast cancer cells

  2023cites this paper
• 18F-FDG Micro PET/CT imaging to evaluate the effect of BRCA1 knockdown on MDA-MB231 breast cancer cell radiosensitivity

  2022cites this paper
• High BRCA1 gene expression increases the risk of early distant metastasis in ER+ breast cancers

  2022cites this paper
• HBXIP is a novel regulator of the unfolded protein response that sustains tamoxifen resistance in ER+ breast cancer

  2022cites this paper
• Effective targeting of breast cancer stem cells by combined inhibition of Sam68 and Rad51

  2022cites this paper
• Overexpressed Cyclin D1 and CDK4 proteins are responsible for the resistance to CDK4/6 inhibitor in breast cancer that can be reversed by PI3K/mTOR inhibitors

  2022cites this paper
• YTHDF1 promotes breast cancer cell growth, DNA damage repair and chemoresistance

  2022cites this paper
• Single-Cell Image-Based Analysis Reveals Chromatin Changes during the Acquisition of Tamoxifen Drug Resistance

  2022cites this paper
• Genome editing and cancer: How far has research moved forward on CRISPR/Cas9?

  2022cites this paper
• Preclinical validation and phase I trial of 4-hydroxysalicylanilide, targeting ribonucleotide reductase mediated dNTP synthesis in multiple myeloma

  2022cites this paper
• Tamoxifen: The Past, Present, and Future of a Previous Orphan Drug

  2022cites this paper
• BARD1 mystery: tumor suppressors are cancer susceptibility genes

  2022cites this paper
• In vitro breast cancer models for studying mechanisms of resistance to endocrine therapy

  2022cites this paper
• Mutual regulation between N6-methyladenosine (m6A) modification and circular RNAs in cancer: impacts on therapeutic resistance

  2022cites this paper
• CRISPR/Cas9 system in breast cancer therapy: advancement, limitations and future scope

  2022cites this paper
• Molecular Docking and in silico Pharmacological Screening of Oleosin from Cocos Nucifera Complexed with Tamoxifen in Developing Potential Breast Chemotherapeutic Leads

  2022cites this paper
• LncRNA H19 Impairs Chemo and Radiotherapy in Tumorigenesis

  2022cites this paper
• Up-regulation of ITGAV and the underlying mechanisms in nasopharyngeal carcinoma

  2022cites this paper
• Checkpoint Kinase 2 Inhibition Can Reverse Tamoxifen Resistance in ER-Positive Breast Cancer

  2022cites this paper
• HAS2-Ezrin-ER axis plays a role in acquired antiestrogen resistance of ER-positive breast cancer

  2022cites this paper
• Ceramide kinase confers tamoxifen resistance in estrogen receptor-positive breast cancer by altering sphingolipid metabolism.

  2022cites this paper
• Reduced expression of RBP7 is associated with resistance to tamoxifen in luminal A breast cancer.

  2022cites this paper
• DNA Repair Genes as Drug Candidates for Early Breast Cancer Onset in Latin America: A Systematic Review

  2021cites this paper
• Falcarindiol Enhances Cisplatin Chemosensitivity of Hepatocellular Carcinoma via Down-Regulating the STAT3-Modulated PTTG1 Pathway

  2021influential citation
• Dinaciclib, a Bimodal Agent Effective against Endometrial Cancer

  2021cites this paper
• RNF19A-mediated ubiquitination of BARD1 prevents BRCA1/BARD1-dependent homologous recombination

  2021cites this paper
• Loss of HAS2 Confers Acquired Antiestrogen Resistance by Upregulating Ezrin Expression in ER-Positive Breast Cancer

  2021cites this paper
• Silver nanoparticles achieve cytotoxicity against breast cancer by regulating long-chain noncoding RNA XLOC_006390-mediated pathway.

  2021cites this paper
• Estrogen receptor—positive breast cancer survival prediction and analysis of resistance–related genes introduction

  2021cites this paper
• Identification of a novel pathogenic variant in PALB2 and BARD1 genes by a multigene sequencing panel in triple negative breast cancer in Morocco

  2021cites this paper
• SNP rs4971059 predisposes to breast carcinogenesis and chemoresistance via TRIM46‐mediated HDAC1 degradation

  2021cites this paper
• EMP3 negatively modulates breast cancer cell DNA replication, DNA damage repair, and stem-like properties

  2021cites this paper
• Centipeda minima extract sensitizes lung cancer cells to DNA-crosslinking agents via targeting Fanconi anemia pathway.

  2021cites this paper
• CRISPR/Cas9 based genome editing for targeted transcriptional control in triple-negative breast cancer

  2021influential citation
• Dexrazoxane ameliorates radiation-induced heart disease in a rat model

  2021cites this paper
• ELOVL2: a novel tumor suppressor attenuating tamoxifen resistance in breast cancer.

  2020cites this paper
• MT2A Promotes Oxaliplatin Resistance in Colorectal Cancer Cells

  2020cites this paper
• The Possible Roles of Long Non-Coding RNAs FOXD2-AS1 and LINC00968 in Breast Cancer: Case-Control Study and in Silico Analysis

  2020cites this paper
• miR-484 suppresses endocrine therapy-resistant cells by inhibiting KLF4-induced cancer stem cells in estrogen receptor-positive cancers

  2020cites this paper
• Compensatory Estrogen Signal Is Capable of DNA Repair in Antiestrogen-Responsive Cancer Cells via Activating Mutations

  2020cites this paper
• The efficacy of first-line chemotherapy in endocrine-resistant hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) metastatic breast cancer

  2020cites this paper
• MT2A Promotes Oxaliplatin Resistance in Colorectal Cancer Cells

  2020cites this paper
• Obg-Like ATPase 1 Enhances Chemoresistance of Breast Cancer via Activation of TGF-β/Smad Axis Cascades

  2020cites this paper